1h Free Analyst Time
The publisher has been monitoring the patient derived xenograft market and it is poised to grow by $188.19 million during 2021-2025, progressing at a CAGR of 16.66% during the forecast period. Our report on the patient derived xenograft market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing demand for personalized medicine and the development of immunodeficient rats. In addition, the growing demand for personalized medicine is anticipated to boost the growth of the market as well.
The patient derived xenograft market analysis includes the application segment and geographic landscape.
The publisher's patient derived xenograft market is segmented as below:
By Application
- Preclinical drug development
- Bio marker analysis
By Geographic
- North America
- Europe
- Asia
- ROW
This study identifies the increasing incidence of lung cancersas one of the prime reasons driving the patient derived xenograft market growth during the next few years.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on patient derived xenograft market covers the following areas:
- Patient derived xenograft market sizing
- Patient derived xenograft market forecast
- Patient derived xenograft market industry analysis
Table of Contents
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Application
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
List of Exhibits
Executive Summary
This publisher is pleased to announce their new report, Global Patient Derived Xenograft Market 2021-2025The publisher recognizes the following companies as the key players in the global patient derived xenograft market: Champions Oncology Inc., Charles River Laboratories International Inc., Experimental Pharmacology and Oncology EPO Berlin Buch GmbH, Hera Biolabs Inc., Oncodesign SA, PerkinElmer Inc., Pharmatest Services Oy, The Jackson Laboratory, UROSPHERE SAS, and WuXi AppTec Co. Ltd.
Commenting on the report, an analyst from the publisher said 'The latest trend gaining momentum in the market is increasing incidence of lung cancers.'
According to the report, one of the major drivers for this market is the growing demand for personalized medicine.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Champions Oncology Inc.
- Charles River Laboratories International Inc.
- Experimental Pharmacology and Oncology EPO Berlin Buch GmbH
- Hera Biolabs Inc.
- Oncodesign SA
- PerkinElmer Inc.
- Pharmatest Services Oy
- The Jackson Laboratory
- UROSPHERE SAS
- WuXi AppTec Co. Ltd.
